PAI-1 and Neoadjuvant Chemotherapy in Breast Cancer
Author Information
Author(s): J-Y Pierga, C Lain-Bidron, P Beuzeboc, P De Cr6moux, P Pouillart, H Magdelenat
Primary Institution: Institute Curie
Hypothesis
Does the level of PAI-1 predict the response to neoadjuvant chemotherapy in breast cancer patients?
Conclusion
PAI-1 is not a predictive marker of response to chemotherapy in breast cancer.
Supporting Evidence
- The objective response rate after four courses of neoadjuvant chemotherapy was 59%.
- PAI-1 levels did not correlate with chemotherapy response.
- Only high S-phase was slightly correlated with response (p=0.05).
- PAI-1 levels were measured before and after chemotherapy with no significant changes.
Takeaway
The study looked at whether a protein called PAI-1 could help predict how well breast cancer patients would respond to chemotherapy, but it found that it doesn't.
Methodology
The study measured PAI-1 levels in tumor samples from 69 breast cancer patients before chemotherapy and evaluated their response after treatment.
Limitations
The study only included patients with operable tumors and excluded those with inflammatory or metastatic breast cancer.
Participant Demographics
Median age of participants was 46 years, with 80% premenopausal and 20% postmenopausal.
Statistical Information
P-Value
0.66
Statistical Significance
p=0.66
Want to read the original?
Access the complete publication on the publisher's website